Glioblastoma is a deadly disease and modest improvement has been made in patient survival in previous decades. At initial diagnosis, treatment consists of maximum safe surgical resection, followed by temozolomide chemoirradiation and then adjuvant temozolomide alone [1]. This treatment results in a median survival of 14.6 months, a 2-year survival of 27.2% and a 5-year survival of 9.8%[1]. At the time of tumor progression, the best available treatment option consists of single-agent bevacizumab, a humanized monoclonal antibody against VEGF, or in combination with irinotecan or other cytotoxic chemotherapies [2]. Although patients experience improved neurological function, this improvement is nevertheless transient and overall survival is not prolonged. Therefore, new treatment strategies are being sought.